Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
COVID-19 Treatment The 3rd Webinar in the COVID-19 series: “COVID-19 Treatment”, will be held on Saturday, 4 December 2021, from 07.00 to 11.30 WIB (West Indonesia Time). This webinar is supported by INA-RESPOND and partners and is free of charge for all participants. Participants will receive IDI SKP and an electronic certificate*. Click here to register for the webinar Click
Review of Current COVID-19 Diagnostics and Opportunities for Further Development. Yan Mardian, Herman Kosasih, Muhammad Karyana, Aaron Neal, Chuen-Yen Lau. Frontiers in Medicine. May 2021. Diagnostic testing plays a critical role in addressing the coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Rapid and accurate diagnostic tests are imperative
ONE YEAR LIVING WITH SARS-COV-2: PROGRESS ON PREVENTION AND TREATMENT The 2nd Webinar in the COVID-19 series: “Diagnosis Update, Pathogenesis, and CO-infections”, was held on Saturday, July 24, 2021, at 07.00-11.30 WIB (West Indonesia Time). This webinar is supported by INA-RESPOND and partners and is free of charge for all participants. Participants will receive IDI
ONE YEAR LIVING WITH SARS-COV-2: PROGRESS ON PREVENTION AND TREATMENT The First Webinar series, “Updates on COVID-19 Vaccine”, was held on Saturday, April 10, 2021, at 08.00-12.00 WIB. This webinar is supported by INA-RESPOND and partners and is free of charge for all participants. Participants will receive IDI SKP and an electronic certificate.
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
